- Study protocol
- Open Access
Exercise to preserve beta cell function in recent-onset type 1 diabetes mellitus (EXTOD) - a study protocol for a pilot randomized controlled trial
Trials volume 14, Article number: 180 (2013)
Exercise has a beta cell preserving effect in patients with type 2 diabetes. This benefit of exercise has not been examined in type 1 diabetes. Significant beta cell function is present at the time of diagnosis of type 1 diabetes and therefore studies of beta cell preservation are ideally conducted immediately after diagnosis.
Many of the variables required to design and power such a study are currently unknown. The aim of EXTOD is to obtain the information required to design a formal study of exercise and beta cell preservation in newly diagnosed patients with type 1 diabetes.
Barriers to exercise will initially be assessed in a qualitative study of newly diagnosed patients. Then, sixty newly diagnosed adult type 1 diabetes patients will be randomized to either conventional treatment or exercise, stratified on beta cell function and fitness. The exercise group will be encouraged to increase their level of activity to a minimum of 150 minutes of moderate to vigorous intensity exercise per week, aiming for 240 minutes per week of exercise for 12 months. Beta cell function will be measured by meal-stimulated C peptide. Primary outcomes are recruitment, adherence to exercise, loss to follow-up, and exercise levels in the non-intervention arm (contamination). The secondary outcome of the study is rate of loss of beta cell function.
The outcomes of the EXTOD study will help define the barriers, uptake and benefits of exercise in adults newly diagnosed with type 1 diabetes. This information will enable design of a formal study to assess the effect of exercise on beta cell preservation in newly diagnosed patients with type 1 diabetes.
Current controlled trials ISRCTN91388505
The natural history of beta cell loss in type 1 diabetes
Type 1 diabetes (T1DM) is a chronic inflammatory autoimmune disease characterized by destruction of insulin producing beta cells and by subsequent insulin deficiency . It affects 0.3% of the UK population, approximately 250,000 people, and its incidence is rising . In the UK, it has been reported to result in a shortening of life expectancy by over 20 years .
The loss of beta cells that results in T1DM is a gradual process, and between 50 and 25% of beta cell function can be present at the time of diagnosis . However this residual function is insufficient to generate the insulin required for metabolic control, and the lack of insulin results in a number of metabolic derangements which if untreated results in death. Patients with T1DM therefore start insulin injection replacement therapy at diagnosis. It has generally been assumed that the remaining beta cells are rapidly and completely destroyed soon after diagnosis. However, recent studies indicate that these cells can persist for over 50 years following diagnosis [5–7], and that their presence is associated with important clinical benefits. These benefits include improved glucose control, reduced retinopathy and nephropathy, and with more than a halving of rates of hypoglycemia [8–11]. These benefits of preservation of beta cell function are significant, and the FDA (USA), and EMEA (Europe) state that even partial preservation of beta cell function ((estimated by a stimulated C peptide > 200 pmol/L - elaborated below)) is a sufficient basis for the licensing of new therapies for T1DM .
What are the benefits of beta cell preservation in people with type 1 diabetes?
Whilst beta cell mass cannot be directly measured, it can be accurately estimated through measurement of stimulated C peptide (a component of the pre-insulin molecule) following a physiological meal stimulus . Meal-stimulated C peptide provides an acceptably accurate estimate of beta cell function for use in studies of beta cell preservation . A meal-stimulated C peptide value of greater than 200 pmol/L is associated with the clinical benefits outlined above. C peptide assay technology has improved over the recent years, and through National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsored standardization workshops, levels of 30 pmol/L can now be measured reliably and reproducibly across different laboratories . More recently, the development of sensitive assays has allowed C peptide detection down to levels of 1.5 pmol/L . Such assays have provided even stronger support for the persistence of beta cell function in people with long standing T1DM, albeit at levels that do not provide independence from insulin injections . Current estimates therefore are that 60% of subjects will have a stimulated C peptide greater than 200 pmol/L at two years following diagnosis, but that C peptide is detectable at lower levels in 64% of people at 50 years after diagnosis .
How can we preserve beta cell function in people with type 1 diabetes?
A number of medicinal products are currently under investigation for the preservation of beta cell function in subjects newly diagnosed with T1DM. They are largely immunomodulatory agents that act by ‘suppressing’ the inflammatory autoimmune process targeting the beta cell. Whilst some of them act to modulate the autoimmune process specifically against beta cell antigens , others act through broad, non-antigen specific immune suppression . Many of these therapies are associated with significant risk of side effects. These include infection or reactivation of latent infection, inflammation at the sites of injection, and the risk of cancer and infection associated with immunosuppressive therapy . Furthermore, these new therapies have yet to demonstrate significant and sustained benefit. Whilst we clearly need to continue investigating such novel therapies, there is also a pressing need to examine new therapies with an acceptable side effect profile, and which potentially could be used as an adjunct to the medicinal products under investigation. We are interested in the role of exercise in this regard.
Can exercise preserve beta cell function in people with type 1 diabetes?
Exercise has been demonstrated to preserve beta cells in animal studies [21–23]. Pancreatic sections from a rat model of insulin deficient diabetes revealed a 33% increase in staining for beta cells, and a 31% increase in beta cell mass following an eight-week exercise program. The mechanisms underlying this effect remain unclear but a significant decease in beta cell apoptosis was reported . Exercise has a recognized anti-inflammatory effect  that may therefore modulate the autoimmune process against the islet.
These beneficial effects of exercise on beta cell function have also been demonstrated in healthy human subjects , and in the context of people with pre- or established type 2 diabetes [27, 28]. Here also, the exercise has been of vigorous intensity with a VO2max of 70%, and of sustained duration. The disposition index used in this study as an estimate of beta cell function, revealed a 27% improvement following a one-week program of exercise in older people with impaired glucose tolerance . More recently, an eight-month exercise program in middle-aged overweight people revealed a 60% improvement in beta cell function and a 20% improvement in insulin resistance with moderate intensity exercise (walking at a slow pace for 60 minutes on three days per week) .
Until recently, many observers have remained skeptical that increases in exercise can be maintained long enough to have any significant impact on diabetes risk or help improve diabetes management. However, large intervention studies targeting subjects with impaired glucose tolerance have demonstrated that a program of lifestyle changes focusing on improved diet and increased exercise is able to delay or possibly prevent the development of type 2 diabetes mellitus (T2DM) over a period of four years [30, 31]. Both studies found lifestyle intervention to result in a 58% reduction in the incidence of diabetes, irrespective of age. Importantly, both studies also showed that it was possible to maintain increased levels of exercise for four years. Furthermore, we ourselves have shown that a program of lifestyle changes focusing on improved diet and increased exercise, reduces insulin resistance, weight, and drug usage and improves diabetes control in newly diagnosed type 2 patients . In this study, we demonstrated that with a simple home-based, ‘unsupervised’ and relatively inexpensive exercise regime we can maintain increased levels of exercise for 12 months.
We therefore believe that regular exercise, if demonstrated to show benefit in patients with residual beta cell function, can be undertaken and maintained by patients with diabetes.
Our hypothesis is that exercise preserves beta cell function in people with T1DM. We base this hypothesis on previous studies of exercise in T2DM, pre-T2DM, and people without diabetes, where exercise is associated with preservation of beta cell function.
In order to test our hypothesis, we will initially undertake a qualitative study to identify barriers to the uptake and adherence to an intensive exercise program, and determine the most acceptable way to monitor exercise levels. We will then undertake a pilot RCT involving an exercise intervention in patients with recent onset T1DM in order to:
Determine the proportion and characteristics of patients with T1DM who would be willing to take part in an RCT of exercise (that is, recruitment rate).
Define the rates of exercise adherence to the intervention and participant drop-out. The unsupervised exercise program will aim to encourage patients to safely increase and maintain their exercise level to at least 150 minutes per week, and aiming for 240 minutes per week of vigorous intensity exercise. A minimum level of 150 minutes per week is recommended by major diabetes organizations [33, 34]. However, to maximize the chances of seeing a benefit in beta cell function, patients will be encouraged to aim for 240 minutes per week.
Determine the rate of exercise uptake in the non-intervention arm (that is, intervention contamination). This issue is important because it has the potential to dilute trial effects, and adjustments for this will need to be made when calculating the sample size for a definitive trial.
Determine the rate of loss of beta cell function (potential effect size) in the intervention and control arm to enable the statistical power calculations for the subsequent definitive trial to be refined.
Determine (as a secondary outcome) whether the 12 months exercise intervention results in a significant preservation of beta cell function.
Methods and design
Setting and recruitment
The study will take place across 19 NHS hospital Trusts in the UK: University Hospital Birmingham, Taunton and Somerset, University Hospitals Bristol, North Bristol, Gloucester Hospitals, Yeovil District Hospitals, East and North Hertfordshire, Mid Yorkshire Hospitals, Oxford University Hospitals, Worcestershire Acute Hospitals, George Eliot Hospital, The Dudley Group, Walsall Healthcare, The Royal Wolverhampton Hospitals, Heart of England, Sandwell and West Birmingham, Weston Area Health, Royal United Hospital Bath and Royal Devon and Exeter Hospital. Recruitment will focus on NHS hospital trusts as the vast majority of patients newly diagnosed with T1DM are referred to hospital for initiation of insulin.
Clinical staff at participating hospitals will identify patients newly diagnosed with T1DM. They will approach these patients about the study and ask permission for their contact details to be forwarded to the EXTOD study team. Interested participants will then be contacted by the study team by telephone and invited to attend their local study centre for a screening visit. At the first visit written informed consent will be obtained by a member of the study team (physician or research nurse). Patients will be considered eligible for enrollment in this trial if they fulfill all the inclusion criteria and none of the exclusion criteria (see Table 1).
The EXTOD study is designed in two phases. Phase 1 is a qualitative study designed to inform on the most feasible and patient-friendly way of motivating patients newly diagnosed with T1DM to undertake and maintain a graded exercise program, and to determine the most acceptable way to monitor exercise levels. This understanding is essential for the conduct of phase 2.
Phase 2 is a pilot RCT to assess uptake, intervention adherence, drop-out rates, and rate of uptake in the usual care group during a 12 month exercise intervention, and the effect of this intervention on beta cell function.
Phase 1 - qualitative study
Patients will be interviewed once face-to-face by a qualitative researcher. The interview format will be flexible to allow for logistics of the large area being covered by the study and interviews will take place either on an individual basis or with two or more patients together as appropriate. Interviews will be semi-structured to ensure that key themes are covered, whilst giving participants the opportunity to freely express their views.
The topic guide will explore participants’ views and experience of type 1 diabetes, and what information they were given about exercise at diagnosis (Table 2). All interviews will be recorded, and interviewing will continue until saturation is reached.
Data collection and analysis will be iterative to allow earlier data to shape later data collection. The transcribed data will be analyzed using constant comparative analysis to identify the emerging themes which comprise interviewees’ views regarding particular issues . Themes from participants of different ages and gender will be compared and differences and similarities noted. Management of data for analysis will be assisted by the software package NVivo (QSR International, Victoria, Australia). Themes and a coding frame will be developed by reading and re-reading of the interview transcripts and through discussions between members of the multi-disciplinary research team.
Information from this phase will be used to refine the intervention developed for phase 2.
Phase 2 - RCT
Patients will be initially screened on the telephone and potentially eligible individuals invited to attend a face-to-face assessment to confirm eligibility (visit 1). Here the study team will obtain informed consent, record their clinical history and conduct a physical examination. Participants will return in a fasting state to undertake baseline tests including the meal-stimulated C peptide measurement (visit 2, Table 3). Participants will return again to undertake Astrand-Rhyming and YMCA/ACSM cycle tests to assess fitness  (visit 3). Two cycle tests will be performed to ensure that we can get an accurate estimation of fitness. A study doctor will see all patients at visit 1.
Randomization will be done according to computer-generated allocation. Patients will be assigned, in a 1:1 ratio, to ‘usual care’ or ‘exercise intervention’. Allocations will remain concealed by the trial coordinator until the patients attends visit 4 when they will be randomized using on-line software. Randomization will be minimized by center, meal-stimulated 90-minute C peptide, and fitness. Due to the nature of the intervention, blinding of the study team to the randomization arm is not possible.
In agreement with the local GPs and hospital doctors, the study team will undertake the ongoing diabetes management of all trial participants for the period of the trial. This is to ensure that similar guidelines for treatment intervention are maintained across all sites. Patients will be seen at baseline, 6 and 12 months by a doctor and any changes in treatment will be made according to strict guidelines, thus ensuring no bias between the two groups. All participants will have eight visits. Those patients randomized to the exercise arm will have a further five telephone consultations (see Table 4).
Usual care will consist of standard dietary and exercise advice after randomization, and at the end of the study. There will also be reviews by a study doctor and nurse at baseline and at 6 and 12 months. At randomization, the dietitian will meet with the patients for 45 minutes to provide education on food intake as well as providing information on insulin and carbohydrate dose adjustment around exercise and hypoglycemia management. Any changes to medication will be made using a standardized staged protocol (see disease management).
Participants allocated this arm will receive dietary advice at baseline as for the usual care arm. Thereafter they will be seen by a physician at 6 and 12 months and will have nurse contact at 2, 4, 8, 12, 16, 20, 30, 36, and 42 weeks. Again, any changes to medication will be made using a standardized staged protocol (see Medical management).
Using goal-oriented motivational interviewing techniques, the aim of the physical activity intervention will be to encourage patients to safely increase and maintain their exercise level to at least 150 minutes per week, and aiming for 240 minutes per week of vigorous intensity exercise per week. This goal will be applied to all participants, regardless of their initial level of physical activity. The activity goal will be achieved gradually over 12 weeks in a step-wise fashion and then maintained for the remainder of the study (see Table 5). During the first week, participants will simply be encouraged to do something active on three to four days per week. This will be based outside the hospital setting and monitored as outlined below. On subsequent weeks, the activity level will be increased to 85, 100, 110, 115, 130 and finally 150 minutes per week. The intensity level will also gradually increase until the patient is performing at an intensity of 75% of their estimated maximum oxygen uptake. If participants do not achieve the physical activity goal within 12 weeks, they will be encouraged to achieve it as soon as possible thereafter. Participants will be encouraged and supported to achieve this goal, and will be instructed that they may accumulate activity throughout each day in bouts of at least 10 minutes. Participants who are active sporadically (for example, seasonally) will be encouraged to achieve the goal consistently throughout every month of the study.
All participants will be instructed to monitor their physical activity on a daily basis throughout the study using a wrist-worn heart rate monitor (Polar, Warwick, England) and physical activity log. The heart rate monitor will be worn whilst conducting exercise and will record the length of exercise and the heart rate during exercise. Participants will be requested to keep a daily log of activity and their blood glucose (BG). Participants will be asked to return the completed activity and BG logs to the research nurse at each visit. These will inform the subsequent discussion, and help monitor and encourage an increase in activity levels.
Use of the diary and heart rate monitor will be taught in the first meetings with the research nurse after randomization. Participants will negotiate appropriate targets with the nurse based initially on baseline values and subsequently on achievement. The setting of negotiated, realistic, achievable targets, and self-monitoring of progress towards these targets, is a key strategy for developing confidence to exercise (self-efficacy) and is a strategy adopted by many regular exercisers. All self-monitoring records will be reviewed by the research nurse. The activity log will be copied and returned to the participant, with written or verbal comments from the research nurse. The comments will highlight examples of positive changes the participant has made and help the participant address any barriers to physical activity encountered.
Participants who have not reached the activity goal of an extra 150 minutes per week of moderate to vigorous physical activity within four months of randomization will be offered further help to reach this target. An appointment will be made with a personal fitness instructor to examine alternative ways of helping them increase their activity. They will also be offered discounted membership at their local leisure center, where they will have access to gym and pool facilities and numerous supervised exercise classes (done through the exercise prescription). However, our previous experience indicates that such additional interventions are likely to be required in only a minority of cases.
Management of T1DM, blood pressure, and lipid profile will be undertaken by the study team for the duration of the study. Any changes in treatment of these features will be made according to NICE guidelines  to keep the risk of performance bias to a minimum.
Glycemic control influences beta cell function, therefore our aim will be to achieve optimal glycemia in both arms of the study. To help with this, all patients will be managed either on insulin pump therapy or on a multiple dose insulin injection regime (fast acting or soluble insulin with each meal and background insulin at night). At each visit, the research nurse will review the patients blood glucose and make changes to insulin dosages if need be, and advice will be given about how to alter carbohydrate intake and insulin dosages to minimize hypoglycemic episodes with exercise and obtain ideal glucose control before, during and after exercise.
The overall aim will be to maintain the following targets: HbA1c concentration lower than 6.5%, blood pressure lower than 140/80 mmHg, total cholesterol concentration lower than 4·0 mmol/L, HDL cholesterol concentration higher than 1·0 mmol/L, LDL cholesterol concentration lower than 2·0 mmol/L, and concentration of triglycerides lower than 2·0 mmol/L.
Information will be collected on the number of patients diagnosed with T1DM, who have been approached and the reasons for not coming into the study, so that a full consort diagram can be generated (see Figure 1).
The clinical examination, and assessment of HbA1c, lipids, and renal and thyroid function constitute part of good clinical care and will inform the clinical management of the patient.
Downloads from the heart rate monitor and review of the exercise diaries will confirm and quantify the exercise being undertaken by patients in the exercise arm. Data from the activity monitors will enable us to assess whether we have managed to increase activity in both arms of the study.
Changes across the study in the C peptide response to a mixed meal will enable us to determine the effect that exercise has on beta cell protection.
Measurement of inflammatory markers will inform on the antiinflammatory effect of exercise. Measurement of islet antibodies will allow confirmation and sub-classification of T1DM for the final analysis of the data.
Written advice on carbohydrate and insulin dose adjustment around exercise will be prepared and distributed to both health care professionals and patients. The study team will keep in contact with subjects as they start and increase their exercise participation so that the risks of hypoglycemia and injury can be minimized. Any such events will be documented and reviewed at the study meetings.
Planned sample size and analyses
A minimum of 30 patients per arm is considered sufficient to provide meaningful data to be obtained from this pilot study, but this will be reconsidered in the light of information gathered in phase 1. An initial recruitment rate of 30% is anticipated followed by a 90% adherence rate to the exercise schedule and a 15% drop-out rate. In order to complete the pilot study with a minimum of 30 patients, this means that 30/(0.85 × 0.9 × 0.3) = 130 patients will need to be approached initially.
With the varying sample sizes described above, estimates and 95% confidence intervals on recruitment rate, exercise adherence rate and drop-out rate will be:
Recruitment rate 30% (22% to 39%)
Adherence rate 90% (76% to 97%)
Drop-out rate 15% (5% to 30%)
Summary statistics (mean, standard deviation (SD), median, interquartile range (IQR), proportions) of demographic and primary outcome variables will be presented separately for intervention and control patients. Also, separately for intervention and control patients, change from baseline to 12 months in fitness related variables listed in Tables 3 and 4 will be estimated together with 95% confidence intervals. Trends over time in fitness related variables will be illustrated graphically. Variability in these changes will also be estimated in order to be able to estimate sample size requirements for a definitive trial. Comparison between intervention and control patients in change from baseline in fitness related variables will be made giving effect size estimates for the definitive trial. Association between fitness and demographic variables will be examined at a preliminary level using correlation analysis and chi-squared. A generalized linear model (GLM) will be used to get an initial impression of significance of differences between intervention and control groups in fitness related variables. Demographic variables and baseline fitness variable levels will be included as covariates. Further analysis will use non-linear mixed model analysis for outcome related fitness variables measures including the 19 sites as a random effect. Variation from site to site will then be used to further assist in the design of the definitive trial. The effect of demographic variables will also be investigated with mixed effect modeling.
The study has received approval from the Birmingham East, North and Solihull Research Ethics Committee, UK and local NHS Research and Development review panels. The study will conform to The International Conference on Harmonization of good clinical practice (GCP) guidelines as well as with the Declaration of Helsinki. A steering committee has been established to monitor the trial.
There is increasing evidence that exercise preserves beta cell function in individuals who are overweight, glucose intolerant or have type 2 diabetes. It is not known whether this is true in people with type 1 diabetes. This pilot study aims to provide data on recruitment rates, adherence to exercise programs, drop-out rates and rate of loss of beta cell function in this group of patients. This information is required to design a formal trial of exercise to preserve beta cell function in newly diagnosed type 1 diabetes.
This study design is of a multi-center, randomized controlled trial and is therefore particularly robust. The length of intervention (one year) is longer than most other studies of exercise in type 1 diabetes. The initial qualitative interviews will provide valuable information on the barriers to exercise in patients with type 1 diabetes in the UK, to enable healthcare practitioners to target exercise advice more effectively.
One of the limitations of the study is the small sample size. Due to the incidence of type 1 diabetes and the age group we are recruiting, it is not possible to recruit large numbers of people with recently diagnosed type 1 diabetes even from multiple centers. As this is a pilot study, one of the primary outcome measures is recruitment rates. If this pilot study shows that recruitment rate is poor, we will explore recruitment from a larger number of centers nationally or internationally. A further limitation is the unsupervised nature of the intervention. This makes assessment of adherence difficult. We are using downloadable heart rate monitors and accelerometer data to validate participants’ exercise diaries.
Whilst this is the first study to look at the effects of exercise on beta cell function in type 1 diabetes, studies have examined other benefits of exercise in this condition. Exercise has been demonstrated to improve fitness, insulin requirement, lipids, insulin resistance and well- being, and to reduce cardiovascular disease and mortality in people with long standing type 1 diabetes .
Preservation of beta cells in new or incipient type 1 diabetes will have benefits to the patient as well as the NHS. For patients, it can help avoid late complications, and for the NHS, it can help reduce the costs associated with treating these complications. Should exercise preserve beta cell function, it would be advantageous and straightforward to enable an educational/motivational program through existing healthcare providers targeted at increasing exercise levels in patients with new type 1 diabetes.
Recruitment commenced in November 2011 and is expected to continue until July 2013. Open to recruitment.
Dr Spiros Fourlanos, Royal Melbourne Hospital, Australia
Professor Tim Barrett, Birmingham Children’s Hospital, Birmingham, UK
Dr Ian Gallen, Buckinghamshire Healthcare NHS Trust, UK.
Good clinical practice
Generalized linear model
Ratings of perceived exertion
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Maximal oxygen consumption
Atkinson MA, Eisenbarth GS: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001, 358 (9277): 221-229. 10.1016/S0140-6736(01)05415-0.
Gardner SG, Bingley PJ, Sawtell PA, Weeks S, Gale EA: Rising incidence of insulin dependent diabetes in children aged under five years in the Oxford region: time trend analysis. The Bart’s-Oxford study group. BMJ. 1997, 315 (7110): 713-717. 10.1136/bmj.315.7110.713.
Making every young person with diabetes matter. Report of the children and young people with diabetes working group. 2007, London: Department of Health Diabetes Policy Team
Sherry NA, Tsai EB, Herold KC: Natural history of beta cell function in type 1 diabetes. Diabetes. 2005, 54 (Suppl 2): S32-S39.
Scholin A: Islet antibodies and remaining beta cell function eight years after diagnosis of diabetes in young adults: a prospective follow-up of the nationwide diabetes incidence study in Sweden. J Intern Med. 2004, 255 (3): 384-391. 10.1046/j.1365-2796.2003.01273.x.
Greenbaum CJ: Preservation of beta cell function in autoantibody positive youth with diabetes. Diabetes Care. 2009, 32 (10): 1839-1844. 10.2337/dc08-2326.
Keenan HA, Sun JK, Levine J: Residual insulin production and pancreatic beta cell turnover after 50 years of diabetes: Joslin medalist study. Diabetes. 2010, 59: 2846-2853. 10.2337/db10-0676.
Montanya E, Fernandez-Castaner M, Soler J: Improved metabolic control preserved beta cell function two years after diagnosis of insulin dependent diabetes mellitus. Diabetes Metab. 1997, 23 (4): 314-319.
The DCCT Research Group: Effect of intensive therapy on residual ß cell function in patients with type I diabetes in the diabetes control and complications trial. Ann Intern Med. 1998, 128: 517-523.
Sjoberg S: Residual insulin production, glycemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1987, 30 (4): 208-213. 10.1007/BF00270417.
Steffes MW: Beta cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003, 26 (3): 832-836. 10.2337/diacare.26.3.832.
Fleming A: What will it take to get therapies approved for type 1 diabetes?. Ann N Y Acad Sci. 2008, 1150: 25-31. 10.1196/annals.1447.043.
Kruszynska YT: Basal and 24-hour C peptide and insulin secretion rate in normal man. Diabetologia. 1987, 30 (1): 16-21. 10.1007/BF01788901.
Ludvigsson J: GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med. 2008, 359 (18): 1909-1920. 10.1056/NEJMoa0804328.
Little RR, Rohlfing CL, Tennill AL: Standardization of C peptide measurements. Clin Chem. 2008, 54: 1023-1026. 10.1373/clinchem.2007.101287.
Wang L, Lovejoy N, Faustman DL: Persistence of prolonged C peptide production in type 1 diabetes with an ultrasensitive C peptide assay. Diabetes Care. 2012, 35: 465-470. 10.2337/dc11-1236.
Greenbaum CJ: Dead or alive?. Diabetes Care. 2012, 35 (3): 459-460. 10.2337/dc11-2441.
Thrower SL, James L, Hall W, Green KM, Arif S, Allen JS, Van-Krinks C, Lozanoska-Ochser B, Marquesini L, Brown S, Wong FS, Dayan CM, Peakman M: Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man phase I safety study. Clin Exp Immunol. 2009, 155 (2): 156-165. 10.1111/j.1365-2249.2008.03814.x.
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA: Teplizumab treatment may improve C peptide responses in participants with type 1 diabetes after the new-onset period: a randomized controlled trial. Diabetologia. 2013, 56 (2): 391-400. 10.1007/s00125-012-2753-4.
Chatenoud L: Immune therapy for type 1 diabetes mellitus - what is unique about anti-CD3 antibodies?. Nat Rev Endocrinol. 2010, 6 (3): 149-157. 10.1038/nrendo.2009.275.
Choi SB, Jang JS, Park S: Estrogen and exercise may enhance beta cell function and mass via insulin receptor substrate 2 induction in ovariectomized diabetic rats. Endocrinology. 2005, 146 (11): 4786-4794. 10.1210/en.2004-1653.
Choi SB, Jang JS, Hong SM, Jun DW, Park S: Exercise and dexamethasone oppositely modulate beta cell function and survival via independent pathways in 90% pancreatectomized rats. J Endocrinology. 2006, 190 (2): 471-482. 10.1677/joe.1.06400.
Coskun O, Ocakci A, Bayraktaroglu T, Kanter M: Exercise training prevents and protects streptozotocin-induced oxidative stress and beta cell damage in rat pancreas. Tohoku J Exp Med. 2004, 203 (3): 145-154. 10.1620/tjem.203.145.
Park S, Hong SM, Lee JE, Sung SR: Exercise improves glucose homeostasis that has been impaired by a high-fat diet by potentiating pancreatic beta cell function and mass through IRS2 in diabetic rats. J Appl Physiol. 2007, 103 (5): 1764-1771. 10.1152/japplphysiol.00434.2007.
Ertek S, Cicero A: Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions. Arch Med Sci. 2012, 8 (5): 794-804.
Dela F, Von Linstow ME, Mikines KJ, Galbo H: Physical training may enhance beta cell function in type 2 diabetes. Am J Physiol Endocrinol Metab. 2004, 287 (5): E1024-E1031. 10.1152/ajpendo.00056.2004.
Bloem CJ, Chang AM: Short-term exercise improves beta cell function and insulin resistance in older people with impaired glucose tolerance. J Clin Endocrinol Metab. 2008, 93: 387-392. 10.1210/jc.2007-1734.
Kitabchi AE, Temprosa M, Knowler WC, Kahn SE, Fowler SE, Haffner SM, Andres R, Saudek C, Edelstein SL, Arakaki R, Murphy MB, Shamoon H, Diabetes Prevention Program Research Group: Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: effects of lifestyle intervention and metformin. Diabetes. 2005, 8: 2404-2414.
Slentz CA, Tanner CJ, Bateman LA, Durheim MT, Huffman KM, Houmard JA, Kraus WE: Effects of exercise training intensity on pancreatic beta cell function. Diabetes Care. 2009, 32 (10): 1807-1811. 10.2337/dc09-0032.
Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, Li H, Li H, Jiang Y, An Y, Shuai Y, Zhang B, Zhang J, Thompson TJ, Gerzoff RB, Roglic G, Hu Y, Bennett PH: The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet. 2008, 371 (9626): 1783-1789. 10.1016/S0140-6736(08)60766-7.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002, 346 (6): 393-403.
Andrews RC, Cooper AR, Montgomery AA, Norcross AJ, Peters TJ, Sharp DJ, Jackson N, Fitzsimons K, Bright J, Coulman K, England CY, Gorton J, McLenaghan A, Paxton E, Polet A, Thompson C, Dayan CM: Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomized controlled trial. Lancet. 2011, 378 (9786): 129-139. 10.1016/S0140-6736(11)60442-X.
Chief Medical Officers of England, Scotland, Wales, and Northern Ireland: Start active, stay active: a report on physical activity from the four home countries’ Chief Medical Officers. Edited by: Helath D. 11 June 2011, UK: Department of Health, Physical activity, Health improvement and protection
American Diabetes Association: Standards of medical care in diabetes - 2012. Diabetes Care. 2012, 35: S11-S63.
Greenhalgh T, Taylor R: Papers that go beyond numbers (qualitative research). BMJ. 1997, 315: 740-743. 10.1136/bmj.315.7110.740.
ACSM’s guidelines for exercise testing and prescription. 2010, Lippincott: Williams and Wilkins, 76-79. Eighth
Swain DP, Abernathy KS, Smith CS, Lee SJ, Bunn SA: Target heart rates for the development of cardiorespiratory fitness. Med Sci Sport Exer. 1994, 26 (1): 112-116.
National Institute for Clinical Excellence: Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults [internet]. 2012, [updated 2010 March]. Available from: http://www.nice.org.uk/CG15
Chimen M, Kennedy A, Nirantharakumar K, Pang TT, Andrews R, Narendran P: What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review. Diabetologia. 2012, 55 (3): 542-551. 10.1007/s00125-011-2403-2.
Funding is provided by the Research for Patient Benefit (RfPB) stream of the National Institute for Health Research UK. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. We also gratefully acknowledge the support of Professor Sue Wilson, Primary Care Clinical Sciences, University of Birmingham.
The authors declare that they have no competing interests.
AD, GD, and SG helped prepare the protocol and provided advice on phase 1 of the study. DT and KS helped prepare the protocol and provided advice on exercise aspects of phase 2 of the study. RH and colleagues in the Primary Care Clinical Trials Unit provided statistical advice. NL, AK, NJ, RA and PN wrote the manuscript with contribution from all co-authors. All authors read and approved the final manuscript.
Nadia Lascar, Amy Kennedy contributed equally to this work.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Lascar, N., Kennedy, A., Jackson, N. et al. Exercise to preserve beta cell function in recent-onset type 1 diabetes mellitus (EXTOD) - a study protocol for a pilot randomized controlled trial. Trials 14, 180 (2013). https://doi.org/10.1186/1745-6215-14-180
- Type 1 diabetes
- Beta cell function
- Physical activity
- C peptide